Agenus Inc AGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
Trading Information
- Previous Close Price
- $6.14
- Day Range
- $5.90–6.26
- 52-Week Range
- $2.71–10.31
- Bid/Ask
- $5.81 / $5.97
- Shares Outstanding
- 45.25M
- Market Cap
- $270.12M
- Volume/Avg
- 711,779 / 925,212
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.09
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 81
- Website
- https://www.agenusbio.com
Valuation
Metric | AGEN |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 2.09 |
Price/Cash Flow | — |
Price/Earnings
AGEN
Financial Strength
Metric | AGEN |
|---|---|
Quick Ratio | 0.55 |
Current Ratio | 0.73 |
Interest Coverage | 1.51 |
Quick Ratio
AGEN
Profitability
Metric | AGEN |
|---|---|
Return on Assets (Normalized) | −10.22% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
AGEN
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|Y^xV^GS | LOCK|^@@yh | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|?m@$v! | LOCK|jjbZ | $95B | |||
| Moderna Inc MRNA | LOCK|vG&s>^ | LOCK|$z | $79B | |||
| argenx SE ADR ARGX | LOCK|Y^c#Y?h | LOCK|#Ng | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|<R>%g^r | LOCK|%cq | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|?@k&h%VX | LOCK|w<Qkv | $30B | |||
| Incyte Corp INCY | LOCK|!TB?FN | LOCK|CD$ | $23B | |||
| BioNTech SE ADR BNTX | LOCK|T^ybM#Z | LOCK|@MN | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|>X@vs$c | LOCK|%<<&% | $19B | |||
| BridgeBio Pharma Inc BBIO | LOCK|>&Xf@< | LOCK|Vr | $15B |